TY - JOUR
T1 - Study protocol of the B-CAST study
T2 - A multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer
AU - Ishiguro, Megumi
AU - Kotake, Kenjiro
AU - Nishimura, Genichi
AU - Tomita, Naohiro
AU - Ichikawa, Wataru
AU - Takahashi, Keiichi
AU - Watanabe, Toshiaki
AU - Furuhata, Tomohisa
AU - Kondo, Ken
AU - Mori, Masaki
AU - Kakeji, Yoshihiro
AU - Kanazawa, Akiyoshi
AU - Kobayashi, Michiya
AU - Okajima, Masazumi
AU - Hyodo, Ichinosuke
AU - Miyakoda, Keiko
AU - Sugihara, Kenichi
N1 - Funding Information:
B-CAST study [TRICC0807] is conducted as a part of joint research of Tokyo Medical and Dental University and the Foundation for Biomedical Research and Innovation (FBRI) on construction of foundation for large-scale translational research, with funding from FBRI. FRBI is financed by manufacturers and distributors of the drugs, but there are no competing interest between these companies and the investigators that require disclosure in connection with the study.
Funding Information:
MI has received consulting fees from Taiho Pharmaceutical Co. Ltd., Bristol-Myers Squibb and Merck Serono Co. Ltd; honoraria from Taiho, Chugai Pharmaceutical Co. Ltd., and Yakult Honsha Co. Ltd. K.Kotake has received consulting fees from Taiho and Chugai; honoraria from Taiho, Chugai, Bristol-Myers, Merck Serono, Yakult Honsha, Otsuka, Daiichi Sankyo Co. Ltd., and MSD K. K. GN has received honoraria from Chugai. NT and WI have received honoraria from Taiho and Chugai. KT has received honoraria from Takeda Pharmaceutical Co. Ltd. TW has received honoraria and research funding from Taiho, Chugai, Daiichi Sankyo, Yakult Honsha, Bristol-Myers, Merck Serono, and Takeda. MM has received honoraria from Taiho. YK has received honoraria from Chugai and Sanofi-Aventis K.K.; research funding from Chugai. IH has received honoraria and research funding from Taiho, Chugai, and Daiichi Sankyo. TF, and K. Kondo, AK, MK, MO, and KM have no competing interest. KS has received consultant fees, research funding and honoraria from Taiho, Chugai, Takeda, Yakult Honsha, Daiichi Sankyo, Bristol-Myers, Merck Serono, and Pfizer Co. Ltd.
PY - 2013/3/25
Y1 - 2013/3/25
N2 - Background: Adjuvant chemotherapy for stage III colon cancer is internationally accepted as standard treatment with established efficacy. Several oral fluorouracil (5-FU) derivatives with different properties are available in Japan, but which drug is the most appropriate for each patient has not been established. Although efficacy prediction of 5-FU derivatives using expression of 5-FU activation/metabolism enzymes in tumors has been studied, it has not been clinically applied. Methods/design: The B-CAST study is a multicenter, prospective cohort study aimed to identify the patients who benefit from adjuvant chemotherapy with each 5-FU regimen, through evaluating the relationship between tumor biomarker expression and treatment outcome. The frozen tumor specimens of patients with stage III colon cancer who receives postoperative adjuvant chemotherapy are examined. Protein expression of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) are evaluated using enzyme-linked immunosorbent assay (ELISA). mRNA expression of TP, DPD, thymidylate synthase (TS) and orotate phosphoribosyl transferase (OPRT) are evaluated using reverse transcription polymerase chain reaction (RT-PCR). The patients' clinical data reviewed are as follow: demographic and pathological characteristics, regimen, drug doses and treatment duration of adjuvant therapy, types and severity of adverse events, disease free survival, relapse free survival and overall survival. Then, relationships among the protein/mRNA expression, clinicopathological characteristics and the treatment outcomes are analyzed for each 5-FU derivative. Discussion: A total of 2,128 patients from the 217 institutions were enrolled between April 2009 and March 2012. The B-CAST study demonstrated that large-scale, multicenter translational research using frozen samples was feasible when the sample shipment and Web-based data collection were well organized. The results of the study will identify the predictors of benefit from each 5-FU derivative, and will contribute to establish the "personalized therapy" in adjuvant chemotherapy for colon cancer. Trial registration: ClinicalTrials.gov: NCT00918827, UMIN Clinical Trials Registry (UMIN-CTR) UMIN000002013.
AB - Background: Adjuvant chemotherapy for stage III colon cancer is internationally accepted as standard treatment with established efficacy. Several oral fluorouracil (5-FU) derivatives with different properties are available in Japan, but which drug is the most appropriate for each patient has not been established. Although efficacy prediction of 5-FU derivatives using expression of 5-FU activation/metabolism enzymes in tumors has been studied, it has not been clinically applied. Methods/design: The B-CAST study is a multicenter, prospective cohort study aimed to identify the patients who benefit from adjuvant chemotherapy with each 5-FU regimen, through evaluating the relationship between tumor biomarker expression and treatment outcome. The frozen tumor specimens of patients with stage III colon cancer who receives postoperative adjuvant chemotherapy are examined. Protein expression of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) are evaluated using enzyme-linked immunosorbent assay (ELISA). mRNA expression of TP, DPD, thymidylate synthase (TS) and orotate phosphoribosyl transferase (OPRT) are evaluated using reverse transcription polymerase chain reaction (RT-PCR). The patients' clinical data reviewed are as follow: demographic and pathological characteristics, regimen, drug doses and treatment duration of adjuvant therapy, types and severity of adverse events, disease free survival, relapse free survival and overall survival. Then, relationships among the protein/mRNA expression, clinicopathological characteristics and the treatment outcomes are analyzed for each 5-FU derivative. Discussion: A total of 2,128 patients from the 217 institutions were enrolled between April 2009 and March 2012. The B-CAST study demonstrated that large-scale, multicenter translational research using frozen samples was feasible when the sample shipment and Web-based data collection were well organized. The results of the study will identify the predictors of benefit from each 5-FU derivative, and will contribute to establish the "personalized therapy" in adjuvant chemotherapy for colon cancer. Trial registration: ClinicalTrials.gov: NCT00918827, UMIN Clinical Trials Registry (UMIN-CTR) UMIN000002013.
UR - http://www.scopus.com/inward/record.url?scp=84875318063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875318063&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-13-149
DO - 10.1186/1471-2407-13-149
M3 - Article
C2 - 23530572
AN - SCOPUS:84875318063
VL - 13
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
M1 - 149
ER -